Physician profile
Matthew Holt
NPI 1487889085
$4,021.80
in general payments reported to CMS, 2019-2025
29 companies · $787 in 2025
The $787 reported for 2025 was more than what 79% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $737 · 2022: $589 · 2023: $1,109 · 2024: $800 · 2025: $787.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,696.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,695.77 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $962.91 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $487.62 | 2021-2025 | |
| Glaxosmithkline, LLC. | $388.21 | 2021-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| Astrazeneca Pharmaceuticals LP | $305.47 | 2021-2025 | Airsupra, Farxiga |
| Lilly USA, LLC | $255.01 | 2021-2025 | Mounjaro, Zepbound |
| Medtronic, INC. | $219.25 | 2022-2025 | Intellis Adaptivestim |
| Pfizer INC. | $207.85 | 2021-2025 | |
| Kowa Pharmaceuticals America, INC. | $151.98 | 2021-2024 | Livalo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $139.91 | 2021-2024 | Ofev |
| Novartis Pharmaceuticals Corporation | $131.88 | 2022-2024 | |
| Vertex Pharmaceuticals Incorporated | $125.00 | 2025 | |
| Astellas Pharma US INC | $97.98 | 2024 | Veozah |
| Bayer Healthcare Pharmaceuticals INC. | $90.57 | 2022-2023 | |
| Edwards Lifesciences Corporation | $62.86 | 2025 | Sapien 3 Ultra Resilia |
| Abbott Laboratories | $58.00 | 2023-2024 | Freestyle Libre 3 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $36.51 | 2025 | |
| Axsome Therapeutics, INC. | $33.20 | 2025 | Sunosi |
| Amgen INC. | $32.97 | 2021-2025 | Krystexxa |
| Esperion Therapeutics, INC. | $29.63 | 2021 | |
| Dynavax Technologies Corporation | $29.53 | 2024 | Heplisav-B |
| Inspire Medical Systems, INC. | $27.92 | 2025 | Inspire |
| Amarin Pharma, INC. | $25.68 | 2021 | |
| Daiichi Sankyo INC. | $24.23 | 2022 | |
| Insulet Corporation | $24.14 | 2025 | Omnipod |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $22.99 | 2025 | Xifaxan |
| Idorsia Pharmaceuticals US INC | $18.07 | 2023 | Quviviq |
| Optinose US, INC. | $15.12 | 2021 | |
| Currax Pharmaceuticals LLC | $13.77 | 2023 | Onzetra Xsail, Contrave |
| Genentech USA, INC. | $3.54 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Holt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.